Avanir Pharmaceuticals (Nasdaq: AVNR) reported earnings on Aug. 8. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q3), Avanir Pharmaceuticals beat expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share dropped.

Gross margins shrank, operating margins expanded, net margins increased.

Revenue details
Avanir Pharmaceuticals reported revenue of $10.5 million. The five analysts polled by S&P Capital IQ predicted sales of $10.2 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $2.5 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.11. The three earnings estimates compiled by S&P Capital IQ predicted -$0.11 per share. GAAP EPS were -$0.11 for Q3 against -$0.13 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 94.7%, 50 basis points worse than the prior-year quarter. Operating margin was -139.6%, 50,750 basis points better than the prior-year quarter. Net margin was -142.6%, 50,520 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $12.9 million. On the bottom line, the average EPS estimate is -$0.09.

Next year's average estimate for revenue is $40.1 million. The average EPS estimate is -$0.46.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 190 members out of 253 rating the stock outperform, and 63 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Avanir Pharmaceuticals a green thumbs-up, and 20 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.40.